double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103(2):391-402.[
(2):391-402.Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023...
[7]Maixnerova D, El Mehdi D, Rizk DV, Zhang H, Tesar V. New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies. J Clin Med. 2022;11(10):2810. Published 2022 May 16. [8]Wu L, Du X, Lu X. Role of telitacicept in the t...
NEJM | Sibeprelimab 治疗 IgA 肾病 2 期临床试验结果发布 IgA 肾病(IgA nephropathy, IgAN)是目前世界范围内最常见的原发性肾小球肾病,约占全部肾活检病例的 10%～40%,原发性肾小球疾病的 20%～50%。IgAN 也是我国最常见的肾小球疾病...
美国食品药品监督管理局（FDA）有条件批准布地奈德（budesonide）治疗原发性 IgA 肾病（IgA nephropathy）...
参考文献 [1]肾医通公众号. [2]Locatelli F, Del Vecchio L, Ponticelli C. Systemic and targeted steroids for the treatment of IgA nephropathy.Clin Kidney J. 2023;16(Suppl 2):ii40-ii46. Published 2023 Dec 4. doi:10.1093/ckj/sfa...
3.Gleeson PJ, O'Shaughnessy MM, Barratt J. IgA nephropathy in adults - Treatment Standard. Nephrol Dial Transplant. 2023 Jul 7:gfad146. 4.Li WW, Peng XF, Liu YY, et al. TLR9 and BAFF: Their expression in patients with IgA nephropathy. Mol Med Rep. 2014;10(3):1469–74. ...
2.IgA nephropathy: Treatment and prognosis.UTD 3The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15. 4.IgA nephropathy: Pathogenesis.UTD. 5.A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.NEJM...
IgA 肾病(IgA nephropathy, IgAN)是目前世界范围内最常见的原发性肾小球肾病,约占全部肾活检病例的 10%～40%,原发性肾小球疾病的 20%～50%。IgAN 也是我国最常见的肾小球疾病,已成为终末期肾病的重要病因。目前针对 IgA 肾病主要以非靶向支持性疗法为主,包括控制血压和改善蛋白尿,必要时激素联用免疫抑制剂治疗...
2024年美国肾脏病学会(ASN)--肾脏周(Kidney Week)上,专注于开发肾脏疾病基因疗法的生物科技公司Purespring Therapeutics展示了其创新基因疗法PS-002治疗原发性免疫球蛋白肾病(IgA nephropathy,IgA肾病)的临床前研究结果。数据显示,该疗法能有效靶向肾脏足细胞,通过调节补体系统激活,减轻IgA肾病模型中的疾病表现,降...